They have done this over and over and over. Each time one of their virus programs looks like its going nowhere they just pivot to a new virus then put their hand out for more money and make it sound like an exciting new opportunity.
So looking at this objectively they could have done this years ago when they had the funds. They have raised money on around 35 occasions including the R&D grants and on every occasion they have previously decided that Hep B was not a priority because HIV, Hep C and Covid all had better odds of success. One by one they drop off a cliff.
So what does that say about this new direction since the others which have ended up costing over $80m haven't achieved a single $ in sales or any deals with BP. Now they will need more money to pursue the least likely option. Thats confidence inspiring. What will it cost to start again with a new virus? Who is going to fund it?
Wouldn't think the undertaker has been able to flog much of their cheap stock from the last CR yet. What price could they raise at? Maybe 0.001 with 1000 free attached options for each share. Any further raising has to be at an absolutely crazy dilution level I would assume.
BIT Price at posting:
0.2¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)